These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37343324)

  • 21. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
    Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
    Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
    Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
    Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.
    Han Z; Zhang Z; Yang X; Li Z; Sang S; Islam MT; Guo AA; Li Z; Wang X; Wang J; Zhang T; Sun Z; Yu L; Wang W; Xiong W; Li G; Jiang Y
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38749538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.
    Shi H; Zhang W; Zhang L; Zheng Y; Dong T
    Front Immunol; 2023; 14():1265202. PubMed ID: 37822932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
    Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
    Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.
    Xu C; Xie XL; Kang N; Jiang HQ
    BMC Gastroenterol; 2023 Sep; 23(1):298. PubMed ID: 37667169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.
    Huang W; Xiong W; Tang L; Chen C; Yuan Q; Zhang C; Zhou K; Sun Z; Zhang T; Han Z; Feng H; Liang X; Zhong Y; Deng H; Yu L; Xu Y; Wang W; Shen L; Li G; Jiang Y
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38179695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
    Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
    Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
    Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y; Wang C; Wang Y; Dai L
    Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
    Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
    Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
    Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
    Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
    Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
    Gibney GT; Weiner LM; Atkins MB
    Lancet Oncol; 2016 Dec; 17(12):e542-e551. PubMed ID: 27924752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma.
    Geidel G; Parnian N; Meß C; Schlepper N; Rünger A; Heidrich I; Hansen I; Smit DJ; Menz A; Pantel K; Schneider SW; Kött J; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Oct; 38(10):2017-2023. PubMed ID: 38877773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.